2019
Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity
Krause P, Kavathas P, Ruddle N. Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity. 2019, 265-276. DOI: 10.1007/978-3-030-25553-4_16.ChaptersSubset of patientsMonoclonal antibodiesSide effectsAutoimmune side effectsRespiratory syncytial virusMinimal side effectsInitial unresponsivenessCheckpoint inhibitorsAdverse eventsField of immunologyCheckpoint inhibitionTreatment failureCytokine inhibitorsSyncytial virusAutoimmune diseasesCancer immunotherapyInhibitory receptorsLate toleranceLung cancerImmune cellsPassive transferImmune regulationImmune responseImmunotherapyLatent infection
2010
Intravenous Streptomycin for Treatment of Mycobacterium tuberculosis Meningitis in an Infant
Courter J, Girotto J, Lobato M, Orcutt D, Burke M, Feder H, Krause P, Cohen‐Abbo A, Salazar J. Intravenous Streptomycin for Treatment of Mycobacterium tuberculosis Meningitis in an Infant. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 2010, 30: 1197-1197. DOI: 10.1592/phco.30.11.1197.Peer-Reviewed Original ResearchMycobacterium tuberculosis meningitisIntravenous streptomycinIntramuscular streptomycinTuberculosis meningitisFour-drug antituberculous regimenMental status changesRight-sided weaknessDaily intramuscular injectionsRoute of administrationLean muscle massMagnetic resonance scansM. tuberculosis strainsMedial temporal lobeAntituberculous regimenAntituberculous therapyCerebral edemaPatient's regimenTuberculous meningitisTreatment failureGastric culturesNasogastric tubeTreatment courseVasogenic edemaAntituberculous drugsIntramuscular injectionEmergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection
Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, Mittleman A, Aguero-Rosenfeld M, Topal J, Krause PJ. Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection. Clinical Infectious Diseases 2010, 50: 381-386. PMID: 20047477, DOI: 10.1086/649859.Peer-Reviewed Original ResearchConceptsDrug regimenB. microtiLevel of immunosuppressionBabesia microti infectionTreatment of babesiosisDrug-resistant strainsEmergence of resistanceActive babesiosisMicrobiologic relapseLaboratory abnormalitiesDrug regimensImmunocompromised patientsOptimal therapyTreatment failureDrug therapyMicroti infectionPatientsClinical case historiesDrug resistanceBabesia microtiInfectionRegimenMicrotiEventual developmentBabesiosis